ストックスクリーナーアプリを入手
28.90
3.92%
-1.18
アフターアワーズ：
28.86
-0.04
-0.14%
前日終値:
$30.08
開ける：
$30.67
24時間の取引高:
2.05M
Relative Volume:
1.04
時価総額：
$2.97B
収益：
$139.74M
当期純損益:
$-79.99M
株価収益率:
-28.45
EPS:
-1.0157
ネットキャッシュフロー:
$-360.05M
1週間 パフォーマンス:
-5.43%
1か月 パフォーマンス:
+17.19%
6か月 パフォーマンス:
+25.27%
1年 パフォーマンス:
+45.81%
1日の値動き範囲:
$28.50
$31.24
1週間の範囲:
$28.50
$31.93
52週間の値動き範囲:
$15.35
$36.44
Beam Therapeutics Inc Stock (BEAM) Company Profile
名前
Beam Therapeutics Inc
セクター
電話
857-327-8775
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
28.90 | 3.09B | 139.74M | -79.99M | -360.05M | -1.0157 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-20 | 開始されました | Canaccord Genuity | Buy |
| 2025-10-09 | 開始されました | Jefferies | Buy |
| 2025-03-28 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-03-10 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-07-23 | 開始されました | H.C. Wainwright | Buy |
| 2024-01-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-12-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-08 | ダウングレード | Jefferies | Buy → Hold |
| 2023-10-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-02-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 開始されました | Citigroup | Buy |
| 2022-06-17 | 開始されました | BMO Capital Markets | Market Perform |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2022-01-05 | 開始されました | Guggenheim | Buy |
| 2021-10-19 | 開始されました | SVB Leerink | Outperform |
| 2021-09-24 | 再開されました | Stifel | Buy |
| 2021-09-10 | 開始されました | BofA Securities | Buy |
| 2021-05-11 | 開始されました | Redburn | Buy |
| 2021-05-04 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 開始されました | Wells Fargo | Overweight |
| 2021-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 開始されました | Stifel | Hold |
| 2020-08-05 | 開始されました | William Blair | Outperform |
| 2020-03-02 | 開始されました | Barclays | Overweight |
| 2020-03-02 | 開始されました | JP Morgan | Overweight |
| 2020-03-02 | 開始されました | Jefferies | Buy |
| 2020-03-02 | 開始されました | Wedbush | Outperform |
すべてを表示
Beam Therapeutics Inc (BEAM) 最新ニュース
Why Beam Therapeutics (BEAM) Is Up 5.3% After TIME100 Spotlight and Vanguard Stake Disclosure - Yahoo Finance
Prime Editing and CRISPR Market is expected to Hit US$ 11.46 - openPR.com
Beam Therapeutics’ TIME Honor Puts Base Editing And Valuation In Focus - Yahoo Finance
Beam Therapeutics Advances Base Editing Platform with Strong Clinical Data - HarianBasis.co
Is Beam Therapeutics Inc. (BEAM) A Good Stock To Buy Now? - Insider Monkey
14 Stocks on Jim Cramer’s Radar: Nokia, Cameco, and AI Stocks’ Dip - Insider Monkey
Jim Cramer Believes Beam Therapeutics Is a “Speculative Situation” - Insider Monkey
Price-Driven Insight from (BEAM) for Rule-Based Strategy - Stock Traders Daily
MSN Money - MSN
Vanguard Capital Mgmt (NASDAQ: BEAM) reports 5.02% ownership stake - Stock Titan
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80 - Moomoo
Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study - Insider Monkey
Concurrent Investment Advisors LLC Invests $2.13 Million in Beam Therapeutics Inc. $BEAM - MarketBeat
10 Best Biotech Stocks with Highest Upside Potential - Insider Monkey
Beam Therapeutics (BEAM) Projected to Post Earnings on Tuesday - MarketBeat
Beam Therapeutics shows rising relative strength; still shy of key benchmark - MSN
Beam Therapeutics (NASDAQ:BEAM) Trading Up 8.4%What's Next? - MarketBeat
Beam Therapeutics (BEAM) Shares Surge 10.7% on Positive Market M - GuruFocus
S&P 500 Holds Near Highs Despite Oil Shock and Weak Breadth Data - Investing.com
Beam Therapeutics (BEAM) Shares Rise Over 10% Amid Positive Mark - GuruFocus
XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday - Benzinga
3 Biotech Stocks That Could Benefit from the Patent Cliff - MarketBeat
Beam Therapeutics (BEAM) H.C. Wainwright 27th Annual Global Investment Conference summary - Quartr
Beam Therapeutics (BEAM) Q4 2025 earnings summary - Quartr
Beam Therapeutics (BEAM) Q3 2024 earnings summary - Quartr
Beam Therapeutics (BEAM) Status Update Summary - Quartr
Beam Therapeutics (BEAM) Jefferies 2024 Global Healthcare Conference Summary - Quartr
Beam Therapeutics (BEAM) Jefferies London Healthcare Conference 2024 Summary - Quartr
Beam Therapeutics Inc. (BEAM) reports Q4 loss, beats revenue estimates - MSN
Stocks flashing renewed technical strength: Beam Therapeutics - MSN
Beam Therapeutics (NASDAQ:BEAM) Trading Down 6.7%What's Next? - MarketBeat
BEAM Stock Price, Quote & Chart | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains? - MSN
Gene Editing Tools Market is expected to Hit US$ 1,700.05 Million - openPR.com
BEAM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BEAM Price Today: Beam Therapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC
This Beam Therapeutics Insider Reduced Their Stake By 42% - 富途牛牛
(BEAM) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Executive pay and board elections at Beam Therapeutics (NASDAQ: BEAM) 2026 virtual meeting - Stock Titan
[ARS] Beam Therapeutics Inc. SEC Filing - Stock Titan
Beam Therapeutics (BEAM) Is Up 20.6% After Positive Gene-Editing Data And New Credit FacilityHas The Bull Case Changed? - Yahoo Finance
BEAM SEC FilingsBeam Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
[144] Beam Therapeutics Inc. SEC Filing - Stock Titan
Sumitomo Mitsui Trust Group Inc. Has $122.23 Million Stock Holdings in Beam Therapeutics Inc. $BEAM - MarketBeat
Baillie Gifford & Co. Boosts Beam Therapeutics Stake by 40% - National Today
Baillie Gifford & Co. Acquires 118,421 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Trading Up 9.1%Here's What Happened - MarketBeat
Beam Therapeutics CEO Sells 30,078 Shares in April 2026 Transaction | Stock UpdateNews and Statistics - IndexBox
Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors. - Yahoo Finance
BofA Securities Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $47 - Moomoo
Beam Therapeutics Inc (BEAM) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):